Inozyme Pharma/$INZY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inozyme Pharma
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
Ticker
$INZY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
67
ISIN
US45790W1080
Website
Inozyme Pharma Metrics
BasicAdvanced
$255M
-
-$1.68
1.34
-
Price and volume
Market cap
$255M
Beta
1.34
52-week high
$6.05
52-week low
$0.72
Average daily volume
3.4M
Financial strength
Current ratio
2.189
Quick ratio
1.982
Long term debt to equity
64.737
Total debt to equity
147.663
Interest coverage (TTM)
-18.70%
Management effectiveness
Return on assets (TTM)
-48.45%
Return on equity (TTM)
-141.69%
Valuation
Price to book
8.02
Price to tangible book (TTM)
8.02
Price to free cash flow (TTM)
-2.599
Growth
Earnings per share change (TTM)
22.93%
3-year earnings per share growth (CAGR)
-13.99%
What the Analysts think about Inozyme Pharma
Analyst ratings (Buy, Hold, Sell) for Inozyme Pharma stock.
Inozyme Pharma Financial Performance
Revenues and expenses
Inozyme Pharma Earnings Performance
Company profitability
Inozyme Pharma News
AllArticlesVideos
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
Business Wire·1 week ago
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
Business Wire·2 weeks ago
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inozyme Pharma stock?
Inozyme Pharma (INZY) has a market cap of $255M as of May 29, 2025.
What is the P/E ratio for Inozyme Pharma stock?
The price to earnings (P/E) ratio for Inozyme Pharma (INZY) stock is 0 as of May 29, 2025.
Does Inozyme Pharma stock pay dividends?
No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of May 29, 2025.
When is the next Inozyme Pharma dividend payment date?
Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.
What is the beta indicator for Inozyme Pharma?
Inozyme Pharma (INZY) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.